Literature DB >> 28587874

Neuropathies in the setting of Neurofibromatosis tumor syndromes: Complexities and opportunities.

Alexander Schulz1, Peter Grafe2, Christian Hagel3, Philipp Bäumer4, Helen Morrison5, Victor-Felix Mautner6, Said Farschtschi7.   

Abstract

The term 'Neurofibromatosis' (NF) comprises a group of rare diseases with related clinical presentations but distinct genetic conditions. All currently known types - NF1, NF2 and Schwannomatosis - predispose afflicted individuals to the development of glial cell-derived (gliogenic) tumors. Furthermore, the occurrence of neuropathic symptoms, which add to the overall neurologic disability of patients, has been described in all disease entities. We show that neuropathic symptoms are a common and clinically important, yet infrequently studied feature in the NF spectrum. However, the clinical relevance and respective underlying pathogenesis, varies greatly among the different NF types. In this review, we summarize and interpret the latest basic research findings, as well as clinical observations, in respect of Neurofibromatosis-associated neuropathies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  NF1; NF2; Nerve microlesions; Neurofibroma; Peripheral neuropathy; Schwannoma; Schwannomatosis

Mesh:

Year:  2017        PMID: 28587874     DOI: 10.1016/j.expneurol.2017.06.006

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

1.  Type-1 neurofibromatosis mimicking multiple mononeuropathy: the help of nerve ultrasound.

Authors:  Daniele Orsucci; Gianluca Moscato; Vincenzo Ricci; Stefano Galletti; Marco Vista
Journal:  Neurol Sci       Date:  2021-03-01       Impact factor: 3.307

Review 2.  Peripheral neuropathy in children and adolescents treated for cancer.

Authors:  Kari L Bjornard; Laura S Gilchrist; Hiroto Inaba; Barthelemy Diouf; Marilyn J Hockenberry; Nina S Kadan-Lottick; Daniel C Bowers; M Eileen Dolan; Nicole J Ullrich; William E Evans; Kirsten K Ness
Journal:  Lancet Child Adolesc Health       Date:  2018-09-01

Review 3.  Emerging therapeutic targets for neurofibromatosis type 1.

Authors:  James A Walker; Meena Upadhyaya
Journal:  Expert Opin Ther Targets       Date:  2018-05-07       Impact factor: 6.902

Review 4.  Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment.

Authors:  Shreya S Bellampalli; Rajesh Khanna
Journal:  Pain       Date:  2019-05       Impact factor: 6.961

Review 5.  Peripheral nerve disease secondary to systemic conditions in children.

Authors:  Jo M Wilmshurst; Robert A Ouvrier; Monique M Ryan
Journal:  Ther Adv Neurol Disord       Date:  2019-08-12       Impact factor: 6.570

6.  C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.

Authors:  Said C Farschtschi; Tina Mainka; Markus Glatzel; Anna-Lena Hannekum; Michael Hauck; Mathias Gelderblom; Christian Hagel; Reinhard E Friedrich; Martin U Schuhmann; Alexander Schulz; Helen Morrison; Hildegard Kehrer-Sawatzki; Jan Luhmann; Christian Gerloff; Martin Bendszus; Philipp Bäumer; Victor-Felix Mautner
Journal:  Int J Mol Sci       Date:  2020-05-18       Impact factor: 5.923

7.  Transcriptomic signature of painful human neurofibromatosis type 2 schwannomas.

Authors:  Phanidhar Kukutla; Sherif G Ahmed; Daniel M DuBreuil; Ahmed Abdelnabi; Murat Cetinbas; Giulia Fulci; Berent Aldikacti; Anat Stemmer-Rachamimov; Scott R Plotkin; Brian Wainger; Ruslan I Sadreyev; Gary J Brenner
Journal:  Ann Clin Transl Neurol       Date:  2021-05-30       Impact factor: 4.511

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.